What are the most common mistakes with CJC-1295 (no DAC)?
The most common CJC-1295 (no DAC) mistakes are using the DAC version expecting the same pulse profile (it's not the same); eating right after the dose; skipping the cycle break. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for CJC-1295 (no DAC) is limited.
Common CJC-1295 (no DAC) mistakes
- Using the DAC version expecting the same pulse profile (it's not the same)
- Eating right after the dose
- Skipping the cycle break
Bloodwork worth tracking
- IGF-1 baseline + week 8
References
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295 — Teichman SL et al., JCEM, 2006
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog — Jetté L et al., Endocrinology, 2005
- Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications — Villegas Meza AD et al., JBJS Reviews, 2026
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on CJC-1295 (no DAC)
Full CJC-1295 (no DAC) breakdownCJC-1295 (no DAC) what it's used forCJC-1295 (no DAC) side effectsCJC-1295 (no DAC) how to take itCJC-1295 (no DAC) who should avoid itCJC-1295 (no DAC) half-lifeCJC-1295 (no DAC) how long to workCJC-1295 (no DAC) legal statusCJC-1295 (no DAC) how it workscjc 1295 vs tesamorelinipamorelin vs cjc 1295cjc 1295 vs sermorelinAsk the AI Coach
Last updated 2026-06-15.